Article thumbnail

Dexamethasone Prophylaxis in Pediatric Open Heart Surgery Is Associated with Increased Blood Long Pentraxin PTX3: Potential Clinical Implications

By Franco Lerzo, Giuseppe Peri, Andrea Doni, Paola Bocca, Fabio Morandi, Angela Pistorio, Anna Maria Carleo, Alberto Mantovani, Vito Pistoia and Ignazia Prigione

Abstract

Glucocorticoid administration before cardiopulmonary bypass (CPB) can reduce the systemic inflammatory response and improve clinical outcome. Long pentraxin PTX3 is a novel inflammatory parameter that could play a protective cardiovascular role by regulating inflammation. Twenty-nine children undergoing open heart surgery were enrolled in the study. Fourteen received dexamethasone (1st dose 1.5 mg/Kg i.v. or i.m. the evening before surgery; 2nd dose 1.5 mg/kg i.v. before starting bypass) and fifteen children served as control. Blood PTX3, short pentraxin C-reactive protein (CRP), interleukin-1 receptor II (IL-1RII), fibrinogen and partial thromboplastin time (PTT) were assayed at different times. PTX3 levels significantly increased during CPB in dexamethasone-treated (+D) and dexamethasone-untreated (−D) subjects, but were significantly higher in +D than −D patients. CRP levels significantly increased both in +D and −D patients in the postoperative days, with values significantly higher in −D than +D patients. Fibrinogen and PTT values were significantly higher in −D than +D patients in the 1st postoperative day. IL-1RII plasma levels increased in the postoperative period in both groups. Dexamethasone prophylaxis in pediatric patients undergoing CPB for cardiac surgery is associated with a significant increase of blood PTX3 that could contribute to decreasing inflammatory parameters and improving patient clinical outcome

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3138045
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). Administration of steroids in pediatric cardiac surgery: impact on clinical outcome and
  2. (2002). B.M¨ uller,G.Peri,A.Donietal.,“High circulatinglevels ofthe IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration,”
  3. (2004). C e l i k ,N .G o r m u s ,S .O k e s l i ,Z .I .G o r m u s ,a n dH . Solak, “Methylprednisolone prevents inflammatory reaction occurring during cardiopulmonary bypass: effects on TNF-α,
  4. (2003). C-reactive protein: a critical update,”
  5. (2008). Cardioprotective function of the long pentraxin
  6. (2008). Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells,”
  7. (2008). Clinical benefit ofsteroiduseinpatientsundergoingcardiopulmonarybypass: a meta-analysis of randomized trials,”
  8. (2000). Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children,”
  9. (2007). Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris,”
  10. (1996). Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients,”
  11. (2004). Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells,”
  12. (2006). Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens,”
  13. (2003). o g i ,a n dA .K .O l s s o n ,“ E ffects of dexamethasone on clinical course, C-reactive protein, S100B protein and von Willebrand factor antigen after paediatric6 Clinical and Developmental Immunology cardiac surgery,”
  14. (2008). Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure,”
  15. (2008). Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening,”
  16. (2005). Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility,”
  17. (2002). Production of the long pentraxin PTX3 in advanced atherosclerotic plaques,”
  18. (2004). Prognostic significance of the long pentraxin
  19. (2000). PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans,”
  20. (2010). Regulation of leukocyte recruitment by the long pentraxin PTX3,”
  21. (2006). Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-γ,”
  22. (2004). Role of the hypothalamicpituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products,”
  23. (2003). S c h r o e d e r ,J .M .P e a r l ,S .M .S c h w a r t z
  24. (2001). Systemic inflammation and cardiac surgery: an update,”
  25. (2004). The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response,”
  26. (2009). The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity,”
  27. (2010). The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases,”
  28. (1994). The type II “receptor” as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor,”
  29. (2009). W a g e n a a r ,M .G .A .G o r i s ,M .H .G a s e me ta l . ,“ L o n g pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis,”